Vectra® DA: A Multi-Biomarker Blood Test for Assessing Disease Activity in Patients with Rheumatoid Arthritis
This presentation will summarize: the development and validation of Vectra DA, the basis for its clinical utility, and how Vectra DA can be helpful to clinical trials of pharmaceutical agents.
Thursday, December 11th, 2014 at 1pm – 2pm EST
Find Out More
Detection of Subclinical Interstitial Lung Disease: A Potential Role for Targeted Blood Biomarker Profiling
The general purpose of our translational research studies is to identify clinical tools for the detection of subclinical parenchymal lung disease.
Standardized Assays for Personalized Immune Response Monitoring
This online seminar provides an overview of research published in Immunity that demonstrates progress in the standardization of assays for personalized immune response monitoring.
Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue using Myriad RBM’s Multiplex ApoptosisMAP™Learn about the creation of Myriad RBM’s fully validated, quantitative ApoptosisMAP and its application in cancer therapy research. The webinar highlights the main features of the service, including the ability to measure key heterodimers in the apoptosis pathway, and describes its utility for identifying responders to apoptosis inducers or other chemotherapeutic regimes.
SMA-MAP: A multiplexed immunoassay biomarker panel for Spinal Muscular AtrophyLearn about an approach used for developing biomarkers in rare, pediatric disease and gain insights on current and future utility of the SMA-MAP panel in SMA and other neuromuscular research.
Translating Preclinical Pharmacology in Clinical ActivityWatch to learn how Myriad RBM’s products and services were used by VentiRx to compare potency, define PK/PD relationships, identify potential clinical biomarkers of VTX-2337 activity and establish a Minimal Anticipated Biological Effect Level (MABEL) for the initial clinical trial.
Drug Induced Kidney Injury Biomarkers: Data From Four SpeciesTranslatability and Utility in Drug Safety Studies and Kidney Disease Research – Find out how this suite of solutions, developed in conjunction with the Predictive Safety Testing Consortium (PSTC), can help you expedite translational development from pre-clinical animal studies to early clinical testing.
How to Implement a Sound Biomarker Strategy to Increase Your Success Rate in Drug Development.Learn how Myriad RBM’s Strategic Biomarker Services can save time and money or even resurrect a late-stage failure.
Recorded webinar coming soon.